Aseptic Filling Machine Market Industry Trends and Global Forecasts to 2035, by Type of Molecule, Type of Packaging Container Offered, Type of Drug Product, Scale of Operation, Company Size, Target Therapeutic Area and Geographical Regions

1.1. Chapter Overview
1.2. Key Insights
1.3. Scope of the Report
1.4. Research Methodology
1.5. Frequently Asked Questions
1.6. Chapter Outlines

3.1. Chapter Overview
3.2. Introduction to Contract Manufacturing
3.3. Commonly Outsourced Operations in Biopharmaceutical Industry
3.3.1. Aseptic Fill Finish Operations
3.4. Basic Guidelines for Selecting a Fill Finish Service Provider
3.5. Advantages of Outsourcing Fill Finish Operations
3.6. Risks and Challenges Associated with Outsourcing Fill Finish Operations
3.7. Concluding Remarks

4.1. Chapter Overview
4.2. Aseptic Fill / Finish: Service Providers Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Location of Headquarters
4.2.4. Analysis by Type of Molecule(s)
4.2.5. Analysis by Type of Packaging Container(s) Offered

5.1. Chapter Overview
5.2. Biologics Fill Finish: Service Providers Landscape
5.2.1. Analysis by Year of Establishment
5.2.2. Analysis by Company Size
5.2.3. Analysis by Location of Headquarters
5.2.4. Analysis by Location of Fill Finish Facilities
5.2.5. Analysis by Type of Packaging Container(s) Offered
5.2.6. Analysis by Type of Drug Product(s) Involved
5.2.7. Analysis by Scale of Operation
5.2.8. Analysis by Additional Drug Product-related Services Offered
5.2.9. Information on Fill Finish Capacity

6.1. Chapter Overview
6.2. Small Molecule Fill Finish: Service Providers Landscape
6.2.1. Analysis by Year of Establishment
6.2.2. Analysis by Company Size
6.2.3. Analysis by Location of Headquarters
6.2.4. Analysis by Location of Fill Finish Facilities
6.2.5. Analysis by Type of Filling Service(s) Offered
6.2.6. Analysis by Type of Finishing Service(s) Offered
6.2.7. Analysis by Type of Packaging Container(s) Offered
6.2.8. Analysis by Scale of Operation
6.2.9. Analysis by Type of Dosage Form(s) Filled
6.2.10. Analysis by Type of Process(es)
6.2.11. Information on Fill Finish Capacity

7.1. Chapter Overview
7.2. Companies Offering Aseptic Fill Finish Services for Biologics
7.2.1. AbbVie Contract Manufacturing
7.2.1.1. Company Snapshot
7.2.1.2. Financial Information
7.2.1.3. Service Portfolio
7.2.1.4. Fill Finish Services Offered
7.2.1.5. Recent Developments and Future Outlook
7.2.2. BioPharma Solutions
7.2.2.1. Company Snapshot
7.2.2.2. Financial Information
7.2.2.3. Service Portfolio
7.2.2.4. Fill Finish Services Offered
7.2.2.5. Recent Developments and Future Outlook
7.2.3. BioReliance
7.2.3.1. Company Snapshot
7.2.3.2. Financial Information
7.2.3.3. Service Portfolio
7.2.3.4. Fill Finish Services Offered
7.2.3.5. Recent Developments and Future Outlook
7.2.4. Catalent Biologics
7.2.4.1. Company Snapshot
7.2.4.2. Financial Information
7.2.4.3. Service Portfolio
7.2.4.4. Fill Finish Services Offered
7.2.4.5. Recent Developments and Future Outlook
7.2.5. Charles River Laboratories
7.2.5.1. Company Snapshot
7.2.5.2. Financial Information
7.2.5.3. Fill Finish Services Offered
7.2.5.4. Recent Developments and Future Outlook
7.2.6. Patheon
7.2.6.1. Company Snapshot
7.2.6.2. Financial Information
7.2.6.3. Service Portfolio
7.2.6.4. Fill Finish Services Offered
7.2.6.5. Recent Developments and Future Outlook
7.3. Companies Offering Aseptic Fill Finish Services for Small Molecules
7.3.1.1. Pfizer CentreOne
7.3.1.2. Company Snapshot
7.3.1.3. Service Portfolio
7.3.1.4. Fill Finish Services Offered
7.3.1.5. Recent Developments and Future Outlook
7.3.2. Plastikon Healthcare
7.3.2.1. Company Snapshot
7.3.2.2. Service Portfolio
7.3.2.3. Fill Finish Services Offered
7.3.2.4. Recent Developments and Future Outlook
7.3.3. Sharp Services
7.3.3.1. Company Snapshot
7.3.3.2. Service Portfolio
7.3.3.3. Fill Finish Services Offered
7.3.3.4. Recent Developments and Future Outlook

8.1. Company Overview
8.2. Companies Offering Aseptic Fill Finish Services for Biologics
8.2.1. Boehringer Ingelheim BioXcellence
8.2.1.1. Company Snapshot
8.2.1.2. Financial Information
8.2.1.3. Service Portfolio
8.2.1.4. Fill Finish Services Offered
8.2.1.5. Recent Developments and Future Outlook
8.2.2. Fareva
8.2.2.1. Company Snapshot
8.2.2.2. Fill Finish Services Offered
8.2.2.3. Recent Developments and Future Outlook
8.2.3. GlaxoSmithKline
8.2.3.1. Company Snapshot
8.2.3.2. Financial Information
8.2.3.3. Fill Finish Services Offered
8.2.3.4. Recent Developments and Future Outlook
8.2.4. Lonza
8.2.4.1. Company Snapshot
8.2.4.2. Financial Information
8.2.4.3. Service Portfolio
8.2.4.4. Fill Finish Services Offered
8.2.4.5. Recent Developments and Future Outlook
8.2.5. Pierre Fabre
8.2.5.1. Company Snapshot
8.2.5.2. Financial Information
8.2.5.3. Service Portfolio
8.2.5.4. Fill Finish Services Offered
8.2.5.5. Recent Developments and Future Outlook
8.2.6. Wacker Biotech
8.2.6.1. Company Snapshot
8.2.6.2. Financial Information
8.2.6.3. Service Portfolio
8.2.6. 4. Fill Finish Services Offered
8.2.6.5. Recent Developments and Future Outlook
8.3. Companies Offering Aseptic Fill Finish Services for Small Molecules
8.3.1. Aenova
8.3.1.1. Company Snapshot
8.3.1.2. Financial Information
8.3.1.3. Service Portfolio
8.3.1.4. Fill Finish Services Offered
8.3.1.5. Recent Developments and Future Outlook
8.3.2. APL
8.3.2.1. Company Snapshot
8.3.2.2. Service Portfolio
8.3.2.3. Fill Finish Services Offered
8.3.2.4. Recent Developments and Future Outlook
8.3.3 CordenPharma
8.3.3.1. Company Snapshot
8.3.3.2. Service Portfolio
8.3.3.3. Fill Finish Services Offered
8.3.3.4. Recent Developments and Future Outlook
8.3.4. Delpharm
8.3.4.1. Company Snapshot
8.3.4.2. Service Portfolio
8.3.4.3. Fill Finish Services Offered
8.3.4.4. Recent Developments and Future Outlook
8.3.5 PiSA Farmaceutica
8.3.5.1. Company Snapshot
8.3.5.2. Service Portfolio
8.3.5.3. Fill Finish Services Offered
8.3.5.4. Recent Developments and Future Outlook
8.4 Companies Offering Aseptic Fill Finish Manufacturing for Biologics and Small Molecules
8.4.1 Fresenius Kabi
8.4.1.1. Company Snapshot
8.4.1.2 Financial Information
8.4.1.3. Service Portfolio
8.4.1.4. Fill Finish Services Offered
8.4.1.5. Recent Developments and Future Outlook
8.4.2 Recipharm
8.4.2.1. Company Snapshot
8.4.2.2. Financial Information
8.4.2.3. Service Portfolio
8.4.2.4. Fill Finish Services Offered
8.4.2.5. Recent Developments and Future Outlook

9.1 Company Overview
9.2 Companies Offering Aseptic Fill Finish Services for Biologics
9.2.1 Asymchem
9.2.1.1. Company Snapshot
9.2.1.2. Financial Information
9.2.1.3. Service Portfolio
9.2.1.4. Fill Finish Services Offered
9.2.1.5. Recent Developments and Future Outlook
9.2.2. Samsung Biologics
9.2.2.1. Company Snapshot
9.2.2.2. Financial Information
9.2.2.3. Service Portfolio
9.2.2.4. Fill Finish Services Offered
9.2.2.5. Recent Developments and Future Outlook
9.2.3. Syngene
9.2.3.1. Company Snapshot
9.2.3.2. Financial Information
9.2.3.3. Service Portfolio
9.2.3.4. Fill Finish Services Offered
9.2.3.5. Recent Developments and Future Outlook
9.2.4. Takara Bio
9.2.4.1. Company Snapshot
9.2.4.2. Financial Information
9.2.4.3. Service Portfolio
9.2.4.4. Fill Finish Services Offered
9.2.4.5. Recent Developments and Future Outlook
9.2.5. WuXi Biologics
9.2.5.1. Company Snapshot
9.2.5.2. Financial Information
9.2.5.3. Service Portfolio
9.2.5.4. Fill Finish Services Offered
9.2.5.5. Recent Developments and Future Outlook
9.2.6. Hetero Drugs
9.2.6.1. Company Snapshot
9.2.6.2. Fill Finish Services Offered
9.2.6.3. Recent Developments and Future Outlook
9.2.7. Intas Pharmaceuticals
9.2.7.1. Company Snapshot
9.2.7.2. Fill Finish Services Offered
9.2.7.3. Recent Developments and Future Outlook
9.3. Companies Offering Aseptic Fill Finish Services for Small Molecules
9.3.1. Siegfried
9.3.1.1. Company Snapshot
9.3.1.2. Financial Information
9.3.1.3. Service Portfolio
9.3.1.4. Fill Finish Services Offered
9.3.1.5. Recent Developments and Future Outlook
9.3.2. Wockhardt
9.3.2.1. Company Snapshot
9.3.2.2. Financial Information
9.3.2.3. Service Portfolio
9.3.2.4. Fill Finish Services Offered
9.3.2.5. Recent Developments and Future Outlook

10.1. Chapter Overview
10.2. Partnership Models
10.3. Aseptic Fill Finish Service Providers: List of Partnerships and Collaborations
10.3.1. Analysis by Year of Partnership
10.3.2. Analysis by Type of Partnership
10.3.3. Analysis by Scale of Operation
10.3.4. Analysis by Type of Molecule(s) Involved
10.3.5. Analysis by Type of Service(s) Offered
10.3.6. Analysis by Type of Process(es) Involved
10.3.7. Analysis by Type of Drug Product(s) Involved
10.3.8. Most Active Players: Analysis by Number of Partnerships
10.3.9. Analysis by Geography
10.3.9.1. Intercontinental and Intracontinental Agreements

11.1. Chapter Overview
11.2. Forecast Methodology
11.3. Overall Aseptic Fill Finish Manufacturing Market, 2023-2035
11.3.1. Aseptic Fill Finish Services Market: Analysis by Type of Molecule, 2023-2035
11.3.2. Aseptic Fill Finish Manufacturing Market: Analysis by Type of Packaging Container Offered, 2023-2035
11.3.3. Aseptic Fill Finish Manufacturing Market: Analysis by Type of Drug Product, 2023-2035
11.3.4. Aseptic Fill Finish Manufacturing Market: Analysis by Target Therapeutic Area, 2023-2035
11.3.5. Aseptic Fill Finish Manufacturing Market: Analysis by Scale of Operation, 2023-2035
11.3.6. Aseptic Fill Finish Manufacturing Market: Analysis by Company Size, 2023-2035
11.3.7. Aseptic Fill Finish Manufacturing Market: Analysis by Geography, 2023-2035
11.4. Aseptic Fill Finish Manufacturing Market for Biologics, 2023-2035
11.4.1. Aseptic Fill Finish Manufacturing Market for Biologics: Analysis by Type of Packaging Container Offered, 2023-2035
11.4.2. Aseptic Fill Finish Manufacturing Market: Analysis by Type of Drug Product, 2023-2035
11.4.3. Aseptic Fill Finish Manufacturing Market for Biologics: Analysis by Target Therapeutic Area, 2023-2035
11.4.4. Aseptic Fill Finish Manufacturing Market for Biologics: Analysis by Scale of Operation, 2023-2035
11.4.5. Aseptic Fill Finish Manufacturing Market for Biologics: Analysis by Company Size, 2023-2035
11.4.6. Aseptic Fill Finish Manufacturing Market for Biologics: Analysis by Geography, 2023-2035
11.5. Aseptic Fill Finish Manufacturing Market for Small Molecules, 2023-2035
11.5.1. Aseptic Fill Finish Manufacturing Market for Small Molecules: Analysis by Type of Packaging Container Offered, 2023-2035
11.5.2. Aseptic Fill Finish Manufacturing Market for Small Molecules: Analysis by Scale of Operation, 2023-2035
11.5.3. Aseptic Fill Finish Manufacturing Market for Small Molecules: Analysis by Company Size, 2023-2035
11.5.4. Aseptic Fill Finish Manufacturing Market for Small Molecules: Analysis by Geography, 2023-2035

12.1. Chapter Overview
12.2. Role of Robotic Systems in Pharmaceutical Industry
12.3. Role of Robotic Systems in Fill / Finish Operation
12.3.1. Types of Robots Used in Pharmaceutical Operations
12.3.2. Advantages Associated with Robotic Systems
12.3.3. Disadvantages Associated with Robotic Systems
12.4.2. Key Considerations for Selecting a Robotic System
12.3. Contract Service Providers: List of Fill Finish Equipment
12.5. Companies Providing Robots for Use in the Pharmaceutical Industry
12.6. Companies Providing Isolator based Aseptic Filling Systems
12.7. Concluding Remarks

13.1. Chapter Overview
13.2. Role of Ready-to-Use Packaging Components in Aseptic Fill Finish Operations
13.2.1. Advantages of Ready to Use Packaging Components
13.2.2. Disadvantages of Ready to Use Packaging Components
13.3. Companies Providing Ready to Use Packaging Components
13.4. Concluding Remarks

15.1 Chapter Overview
15.2 IDT Biologika
15.2.1. Company Snapshot
15.2.1. Interview Transcript: Former Chief Commercial Officer
15.3 Cytovance Biologics
15.3.1. Company Snapshot
15.3.2. Interview Transcript: Former Vice President of Business Development and Marketing
15.4. Syngene
15.4.1. Company Snapshot
15.4.2. Interview Transcript: Vice President and Head of Formulation Development
15.5 oncomed manufacturing
15.5.1. Company Snapshot
15.5.2. Interview Transcript: Head of Business Development
15.6 Yposkesi
15.6.1. Company Snapshot
15.6.2. Interview Transcript: Former Technology Watch Manager
15.7 HALIX
15.7.1. Company Snapshot
15.7.2. Interview Transcript: International Business Developer

Figure 2.1 Executive Summary: Market Landscape of Biologics Fill Finish Service Providers
Figure 2.2 Executive Summary: Market Landscape of Small Molecules Fill Finish Service Providers
Figure 2.3 Executive Summary: Partnerships and Collaborations
Figure 2.4 Executive Summary: Market Forecast and Opportunity Analysis
Figure 3.1 Types of Third-Party Service Providers
Figure 3.2 Commonly Outsourced Fill Finish Operations
Figure 3.3 Steps Involved in Aseptic Fill Finish Process
Figure 3.4 Blow-Fill-Seal Process
Figure 3.5 Key Considerations for Selecting a CMO Partner
Figure 3.6 Risks and Challenges Associated with Outsourcing Aseptic Fill Finish Operations
Figure 4.1 Aseptic Fill Finish Service Providers: Distribution by Year of Establishment
Figure 4.2 Aseptic Fill Finish Service Providers: Distribution by Company Size
Figure 4.3 Aseptic Fill Finish Service Providers: Distribution by Location of Headquarters
Figure 4.4 Aseptic Fill Finish Service Providers: Distribution by Type of Molecule(s)
Figure 4.5 Aseptic Fill Finish Service Providers: Distribution by Type of Packaging Container(s) Offered
Figure 5.1 Biologics Fill Finish Service Providers: Distribution by Year of Establishment
Figure 5.2 Biologics Fill Finish Service Providers: Distribution by Company Size
Figure 5.3 Biologics Fill Finish Service Providers: Distribution by Location of Headquarters
Figure 5.4 Biologics Fill Finish Service Providers: Distribution by Location of Fill Finish Facilities
Figure 5.5 Biologics Fill Finish Service Providers: Distribution by Type of Packaging Container(s) Offered
Figure 5.6 Biologics Fill Finish Service Providers: Distribution by Type of Packaging Container(s) Offered and Type of Drug Product(s) Involved
Figure 5.7 Biologics Fill Finish Service Providers: Distribution by Scale of Operation
Figure 5.8 Biologics Fill Finish Service Providers: Distribution by Additional Drug Product-related Services Offered
Figure 6.1 Small Molecules Fill Finish Service Providers: Distribution by Year of Establishment
Figure 6.2 Small Molecules Fill Finish Service Providers: Distribution by Company Size
Figure 6.3 Small Molecules Fill Finish Service Providers: Distribution by Location of Headquarters
Figure 6.4 Small Molecules Fill Finish Service Providers: Distribution by Location of Fill / Finish Facilities
Figure 6.5 Small Molecules Fill Finish Service Providers: Distribution by Type of Filling Service(s) Offered
Figure 6.6 Small Molecules Fill Finish Service Providers: Distribution by Type of Finishing Service(s) Offered
Figure 6.7 Small Molecules Fill Finish Service Providers: Distribution by Type of Packaging Container(s) Offered
Figure 6.8 Small Molecules Fill Finish Service Providers: Distribution by Scale of Operation
Figure 6.9 Small Molecules Fill Finish Service Providers: Distribution by Type of Dosage Form(s) Filled
Figure 6.10 Small Molecules Fill Finish Service Providers: Distribution by Type of Process(es)
Figure 7.1 AbbVie: Annual Revenues, 2017-H1 2022 (USD Billion)
Figure 7.2 Baxter (a parent company of BioPharma Solutions): Annual Revenues, 2017-H1 2022 (USD Billion)
Figure 7.3 Merck (a parent company of BioReliance): Annual Revenues, 2017-H1 2022 (EUR Billion)
Figure 7.4 Catalent Biologics: Annual Revenues, FY 2017-FY 2022 (USD Billion)
Figure 7.5 Charles River Laboratories: Annual Revenues, 2017-H1 2022 (USD Billion)
Figure 7.6 Thermo Fisher Scientific (a parent company of Patheon): Annual Revenues, 2017-H1 2022 (USD Billion)
Figure 7.7 Pfizer CentreOne: Annual Revenues, 2017-9M 2022 (USD Million)
Figure 8.1 Boehringer Ingelheim (a parent company of Boehringer Ingelheim BioXcellence): Annual Revenues, 2017-H1 2022 (EUR Billion)
Figure 8.2 GlaxoSmithKline: Annual Revenues, 2017 -H1 2022 (GBP Billion)
Figure 8.3 Lonza: Annual Revenues, 2017-H1 2022 (CHF Billion)
Figure 8.4 Pierre Fabre: Annual Revenues, 2018- 2021 (EUR Billion)
Figure 8.5 Wacker Chemie ( a parent company of Wacker Biotech): Annual Revenues, 2017-H1 2022 (EUR Billion)
Figure 8.6 Aenova: Annual Revenues, 2018-2021 (EUR Million)
Figure 8.7 Fresenius Kabi: Annual Revenues, 2017-9M 2022 (EUR Billion)
Figure 8.8 Recipharm: Annual Revenues, 2017- 2020 (SEK Billion)
Figure 8.9 Recipharm: Revenues by Business Divisions, 2020 (SEK Billion)
Figure 9.1 Asymchem: Annual Revenues, 2017-2020 (USD Billion)
Figure 9.2 Samsung Biologics: Annual Revenues, 2017-H1 2022 (KRW Billion)
Figure 9.3 Syngene: Annual Revenues, FY 2017-FY 2022 (INR Million)
Figure 9.4 Takara Bio: Annual Revenues, FY 2017-FY 2022 (JPY Billion)
Figure 9.5 WuXi Biologics: Annual Revenues, 2017-H1 2022 (RMB Million)
Figure 9.6 Siegfried: Annual Revenues, 2017-H1 2022 (CHF Million)
Figure 9.7 Wockhardt: Annual Revenues, FY 2017- FY Q1 2023 (INR Billion)
Figure 10.1 Partnerships and Collaborations: Cumulative Year wise Trend, 2013-2022
Figure 10.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 10.3 Partnerships and Collaborations: Distribution by Scale of Operation
Figure 10.4 Partnerships and Collaborations: Distribution by Type of Molecule(s) Involved
Figure 10.5 Partnerships and Collaborations: Distribution by Type of Service(s) Offered
Figure 10.6 Partnerships and Collaborations: Distribution by Type of Process(es) Involved
Figure 10.7 Partnerships and Collaborations: Distribution by Type of Drug Product(s) Involved
Figure 10.8 Most Active Players: Distribution by Number of Partnerships
Figure 10.9 Partnerships and Collaborations: Distribution by Geography
Figure 10.10 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Figure 11.1 Global Aseptic Fill Finish Manufacturing Market, 2023-2035 (USD Billion)
Figure 11.2 Aseptic Fill Finish Manufacturing Market: Distribution by Type of Molecule, 2023-2035 (USD Billion)
Figure 11.3 Aseptic Fill Finish Manufacturing Market: Distribution by Type of Packaging Container Offered, 2023-2035 (USD Billion)
Figure 11.4 Aseptic Fill Finish Manufacturing Market: Distribution by Type of Drug Product, 2023-2035 (USD Billion)
Figure 11.5 Aseptic Fill Finish Manufacturing Market: Distribution by Target Therapeutic Area, 2023-2035 (USD Billion)
Figure 11.6 Aseptic Fill Finish Manufacturing Market: Distribution by Scale of Operation, 2023-2035 (USD Billion)
Figure 11.7 Aseptic Fill Finish Manufacturing Market: Distribution by Company Size, 2023-2035 (USD Billion)
Figure 11.8 Aseptic Fill Finish Manufacturing Market: Distribution by Geography, 2023-2035 (USD Billion)
Figure 11.9 Aseptic Fill Finish Manufacturing Market for Biologics, 2023-2035 (USD Billion)
Figure 11.10 Aseptic Fill Finish Manufacturing Market for Biologics: Distribution by Type of Packaging Container Offered, 2023-2035 (USD Billion)
Figure 11.11 Aseptic Fill Finish Manufacturing Market for Biologics: Distribution by Type of Drug Product, 2023-2035 (USD Billion)
Figure 11.12 Aseptic Fill Finish Manufacturing Market for Biologics: Distribution by Target Therapeutic Area, 2023-2035 (USD Billion)
Figure 11.13 Aseptic Fill Finish Manufacturing Market for Biologics: Distribution by Scale of Operation, 2023-2035 (USD Billion)
Figure 11.14 Aseptic Fill Finish Manufacturing Market for Biologics: Distribution by Company Size, 2023-2035 (USD Billion)
Figure 11.15 Aseptic Fill Finish Manufacturing Market for Biologics: Distribution by Geography, 2023-2035 (USD Billion)
Figure 11.16 Aseptic Fill Finish Manufacturing Market for Small Molecules, 2023-2035 (USD Billion)
Figure 11.17 Aseptic Fill Finish Manufacturing Market for Small Molecules: Distribution by Type of Packaging Container Offered, 2023-2035 (USD Billion)
Figure 11.18 Aseptic Fill Finish Manufacturing Market for Small Molecules: Distribution by Scale of Operation, 2023-2035 (USD Billion)
Figure 11.19 Aseptic Fill Finish Manufacturing Market for Small Molecules: Distribution by Company Size, 2023-2035 (USD Billion)
Figure 11.20 Aseptic Fill Finish Manufacturing Market for Small Molecules: Distribution by Geography, 2023-2035 (USD Billion)
Figure 12.1 Key Considerations for Selecting a Robotic System
Figure 12.2 Advantages of Robotic Systems in Pharmaceutical Operations
Figure 13.1 Key Drivers of Ready-to-Use Platform
Figure 14.1 Concluding Remarks: Current Biologic Fill Finish Service Providers Market Landscape
Figure 14.2 Concluding Remarks: Current Small Molecule Fill / Finish Service Providers Market Landscape
Figure 14.3 Concluding Remarks: Partnerships and Collaborations
Figure 14.4 Concluding Remarks: Market Sizing and Opportunity Analysis

Table 4.1 Aseptic Fill Finish Service Providers: List of Companies
Table 4.2 Aseptic Fill Finish Service Providers: Information on Type of Packaging Container(s) Offered
Table 5.1 Biologics Fill Finish Service Providers: List of Companies
Table 5.2 Biologics Fill Finish Service Providers: Information on Type of Packaging Container(s) Offered
Table 5.3 Biologics Fill Finish Service Providers: Information on Type of Drug Product(s) Involved
Table 5.4 Biologics Fill Finish Service Providers: Information on Scale of Operation
Table 5.5 Biologics Fill Finish Service Providers: Information on Additional Drug Product-related Services Offered
Table 5.6 Biologics Fill Finish Service Providers: Information on Fill Finish Capacity
Table 6.1 Small Molecules Fill Finish Service Providers: List of Companies
Table 6.2 Small Molecules Fill Finish Service Providers: Information on Fill Finish Technique
Table 6.3 Small Molecules Fill Finish Service Providers: Information on Type of Packaging Container(s) Offered
Table 6.4 Small Molecules Fill Finish Service Providers: Information on Scale of Operation
Table 6.5 Small Molecules Fill Finish Service Providers: Information on Type of Dosage Form(s) Filled and Type of Process(es)
Table 6.6 Small Molecules Fill Finish Service Providers: Information on Fill Finish Capacity
Table 7.1 Biologics Fill Finish Service Providers: List of Companies Profiled
Table 7.2 AbbVie Contract Manufacturing: Company Snapshot
Table 7.3 AbbVie Contract Manufacturing: Service Portfolio
Table 7.4 AbbVie Contract Manufacturing: Fill Finish Manufacturing
Table 7.5 AbbVie Contract Manufacturing: Sterile Manufacturing Facilities
Table 7.6 AbbVie Contract Manufacturing: Recent Developments and Future Outlook
Table 7.7 BioPharma Solutions: Company Snapshot
Table 7.8 BioPharma Solutions: Service Portfolio
Table 7.9 BioPharma Solutions: Fill Finish Manufacturing
Table 7.10 BioPharma Solutions: Sterile Manufacturing Facilities
Table 7.11 BioPharma Solutions: Recent Developments and Future Outlook
Table 7.12 BioReliance: Company Snapshot
Table 7.13 BioReliance: Service Portfolio
Table 7.14 BioReliance: Fill Finish Manufacturing
Table 7.15 BioReliance: Sterile Manufacturing Facilities
Table 7.16 BioReliance: Recent Developments and Future Outlook
Table 7.17 Catalent Biologics: Company Snapshot
Table 7.18 Catalent Biologics: Service Portfolio
Table 7.19 Catalent Biologics: Fill Finish Manufacturing
Table 7.20 Catalent Biologics: Sterile Manufacturing Facilities
Table 7.21 Catalent Biologics: Recent Developments and Future Outlook
Table 7.22 Charles River Laboratories: Company Snapshot
Table 7.23 Charles River Laboratories: Fill Finish Manufacturing
Table 7.24 Charles River Laboratories: Sterile Manufacturing Facilities
Table 7.25 Charles River Laboratories: Recent Developments and Future Outlook
Table 7.26 Patheon: Company Snapshot
Table 7.27 Patheon: Service Portfolio
Table 7.28 Patheon: Fill Finish Manufacturing
Table 7.29 Patheon: Recent Developments and Future Outlook
Table 7.30 Small Molecules Fill Finish Service Providers: List of Companies Profiled
Table 7.31 Pfizer CentreOne: Company Snapshot
Table 7.32 Pfizer CentreOne: Service Portfolio
Table 7.33 Pfizer CentreOne: Fill Finish Manufacturing
Table 7.34 Pfizer CentreOne: Recent Developments and Future Outlook
Table 7.35 Plastikon Healthcare: Company Snapshot
Table 7.36 Plastikon Healthcare: Service Portfolio
Table 7.37 Plastikon Healthcare: Fill Finish Manufacturing
Table 7.38 Sharp Services: Company Snapshot
Table 7.39 Sharp Services: Service Portfolio
Table 7.40 Sharp Services: Fill Finish Manufacturing
Table 7.41 Sharp Services: Recent Developments and Future Outlook
Table 8.1 Biologics Fill / Finish Service Providers in Europe: List of Companies Profiled
Table 8.2 Boehringer Ingelheim BioXcellence: Company Snapshot
Table 8.3 Boehringer Ingelheim BioXcellence: Service Portfolio
Table 8.4 Boehringer Ingelheim BioXcellence: Fill Finish Manufacturing
Table 8.5 Boehringer Ingelheim BioXcellence: Sterile Manufacturing Facilities
Table 8.6 Boehringer Ingelheim BioXcellence: Recent Developments and Future Outlook
Table 8.7 Fareva: Company Snapshot
Table 8.8 Fareva: Fill Finish Manufacturing
Table 8.9 Fareva: Recent Developments and Future Outlook
Table 8.10 Glaxo SmithKline: Company Snapshot
Table 8.11 Glaxo SmithKline: Fill Finish Manufacturing
Table 8.12 Glaxo SmithKline: Recent Developments and Future Outlook
Table 8.13 Lonza: Company Snapshot
Table 8.14 Lonza: Service Portfolio
Table 8.15 Lonza: Fill Finish Manufacturing
Table 8.16 Lonza: Recent Developments and Future Outlook
Table 8.17 Pierre Fabre: Company Snapshot
Table 8.18 Pierre Fabre: Service Portfolio
Table 8.19 Pierre Fabre: Fill Finish Manufacturing
Table 8.20 Pierre Fabre: Sterile Manufacturing Facilities
Table 8.21 Pierre Fabre: Recent Developments and Future Outlook
Table 8.22 Wacker Biotech: Company Snapshot
Table 8.23 Wacker Biotech: Service Portfolio
Table 8.24 Wacker Biotech: Fill Finish Manufacturing
Table 8.25 Wacker Biotech: Sterile Manufacturing Facilities
Table 8.26 Wacker Biotech: Recent Developments and Future Outlook
Table 8.27 Small Molecules Fill Finish Service Providers in Europe: List of Companies Profiled
Table 8.28 Aenova: Company Snapshot
Table 8.29 Aenova: Service Portfolio
Table 8.30 Aenova: Fill Finish Manufacturing
Table 8.31 Aenova: Recent Developments and Future Outlook
Table 8.32 APL: Company Snapshot
Table 8.33 APL: Service Portfolio
Table 8.34 APL: Fill Finish Manufacturing
Table 8.35 CordenPharma: Company Snapshot
Table 8.36 CordenPharma: Service Portfolio
Table 8.37 CordenPharma: Fill Finish Manufacturing
Table 8.38 CordenPharma: Recent Developments and Future Outlook
Table 8.39 Delpharm: Company Snapshot
Table 8.40 Delpharm: Service Portfolio
Table 8.41 Delpharm: Fill Finish Manufacturing
Table 8.42 Delpharm: Recent Developments and Future Outlook
Table 8.43 PiSA Farmaceutica: Company Snapshot
Table 8.44 PiSA Farmaceutica: Fill Finish Manufacturing
Table 8.45 Biologics and Small Molecules Fill Finish Service Providers in Europe: List of Companies Profiled
Table 8.46 Fresenius Kabi: Company Snapshot
Table 8.47 Fresenius Kabi: Fill Finish Manufacturing
Table 8.48 Recipharm: Company Snapshot
Table 8.49 Recipharm: Service Portfolio
Table 8.50 Recipharm: Fill Finish Manufacturing
Table 8.51 Recipharm: Recent Developments and Future Outlook
Table 9.1 Biologics Fill Finish Service Providers in Asia-Pacific: List of Companies Profiled
Table 9.2 Asymchem: Company Snapshot
Table 9.3 Asymchem: Service Portfolio
Table 9.4 Asymchem: Fill Finish Manufacturing
Table 9.5 Asymchem: Sterile Manufacturing Facilities
Table 9.6 Asymchem: Recent Developments and Future Outlook
Table 9.7 Samsung Biologics: Company Snapshot
Table 9.8 Samsung Biologics: Service Portfolio
Table 9.9 Samsung Biologics: Fill Finish Manufacturing
Table 9.10 Samsung Biologics: Recent Developments and Future Outlook
Table 9.11 Syngene: Company Snapshot
Table 9.12 Syngene: Service Portfolio
Table 9.13 Syngene: Fill Finish Manufacturing
Table 9.14 Syngene: Recent Developments and Future Outlook
Table 9.15 Takara Bio: Company Snapshot
Table 9.16 Takara Bio: Service Portfolio
Table 9.17 Takara Bio: Fill Finish Manufacturing
Table 9.18 Takara Bio: Recent Developments and Future Outlook
Table 9.19 WuXi Biologics: Company Snapshot
Table 9.20 WuXi Biologics: Services Portfolio
Table 9.21 Wuxi Biologics: Fill Finish Manufacturing
Table 9.22 WuXi Biologics: Sterile Manufacturing Facilities
Table 9.23 WuXi Biologics: Recent Developments and Future Outlook
Table 9.24 Hetero Drugs: Company Snapshot
Table 9.25 Hetero Drugs: Fill Finish Manufacturing
Table 9.26 Intas Pharmaceuticals: Company Snapshot
Table 9.27 Intas Pharmaceuticals: Fill Finish Manufacturing
Table 9.28 Small Molecules Fill / Finish Service Providers in Asia-Pacific: List of Companies Profiled
Table 9.29 Siegfried: Company Snapshot
Table 9.30 Siegfried: Service Portfolio
Table 9.31 Siegfried: Fill Finish Manufacturing
Table 9.32 Siegfried: Recent Developments and Future Outlook
Table 9.33 Wockhardt: Company Snapshot
Table 9.34 Wockhardt: Fill Finish Manufacturing
Table 9.35 Wockhardt: Recent Developments and Future Outlook
Table 10.1 Aseptic Fill Finish Service Providers: Partnerships and Collaborations
Table 10.2 Partnerships and Collaborations: Information on Type of Molecule(s) Involved and Type of Service(s) Offered
Table 10.3 Partnerships and Collaborations: Information on Type of Drug Product(s) Involved and Type of Process(es) Involved
Table 12.1 Contract Service Providers: Information on Fill Finish Equipment
Table 12.2 List of Pharmaceutical Robotics Manufacturers
Table 12.3 Isolator based Aseptic Filling Systems: Information on Compatible Primary Container
Table 13.1 List of Companies Supplying Ready-to-Use Aseptic Packaging Components
Table 16.1 Aseptic Fill Finish Service Providers: Distribution by Year of Establishment
Table 16.2 Aseptic Fill Finish Service Providers: Distribution by Company Size
Table 16.3 Aseptic Fill Finish Service Providers: Distribution by Location of Headquarters
Table 16.4 Aseptic Fill Finish Service Providers: Distribution by Type of Molecule(s)
Table 16.5 Aseptic Fill Finish Service Providers: Distribution by Type of Packaging Container(s) Offered
Table 16.6 Biologics Fill Finish Service Providers: Distribution by Year of Establishment
Table 16.7 Biologics Fill Finish Service Providers: Distribution by Company Size
Table 16.8 Biologics Fill Finish Service Providers: Distribution by Location of Headquarters
Table 16.9 Biologics Fill Finish Service Providers: Distribution by Location of Fill Finish Facilities
Table 16.10 Biologics Fill Finish Service Providers: Distribution by Type of Packaging Container(s) Offered
Table 16.11 Biologics Fill Finish Service Providers: Distribution by Type of Packaging Container(s) Offered and Type of Drug Product(s) Involved
Table 16.12 Biologics Fill Finish Service Providers: Distribution by Scale of Operation
Table 16.13 Biologics Fill Finish Service Providers: Distribution by Additional Drug Product-related Services Offered
Table 16.14 Small Molecules Fill Finish Service Providers: Distribution by Year of Establishment
Table 16.15 Small Molecules Fill Finish Service Providers: Distribution by Company Size
Table 16.16 Small Molecules Fill Finish Service Providers: Distribution by Location of Headquarters
Table 16.17 Small Molecules Fill Finish Service Providers: Distribution by Location of Fill Finish Facilities
Table 16.18 Small Molecules Fill Finish Service Providers: Distribution by Type of Filling Service(s) Offered
Table 16.19 Small Molecules Fill Finish Service Providers: Distribution by Type of Finishing Service(s) Offered
Table 16.19 Small Molecules Fill Finish Service Providers: Distribution by Type of Packaging Container(s) Offered
Table 16.20 Small Molecules Fill Finish Service Providers: Distribution by Scale of Operation
Table 16.21 Small Molecules Fill Finish Service Providers: Distribution by Type of Dosage Form(s) Filled
Table 16.22 Small Molecules Fill Finish Service Providers: Distribution by Type of Process(es)
Table 16.23 AbbVie: Annual Revenues, 2017-H1 2022 (USD Billion)
Table 16.24 Baxter (a parent company of BioPharma Solutions): Annual Revenues, 2017-H1 2022 (USD Billion)
Table 16.25 Merck (a parent company of BioReliance): Annual Revenues, 2017-H1 2022 (EUR Billion)
Table 16.26 Catalent Biologics: Annual Revenues, FY 2017-FY 2022 (USD Billion)
Table 16.27 Charles River Laboratories: Annual Revenues, 2017-H1 2022 (USD Billion)
Table 16.28 Thermo Fisher Scientific (a parent company of Patheon): Annual Revenues, 2017-H1 2022 (USD Billion)
Table 16.29 Pfizer CentreOne: Annual Revenues, 2017-9M 2022 (USD Million)
Table 16.30 Boehringer Ingelheim (a parent company of Boehringer Ingelheim BioXcellence): Annual Revenues, 2017-H1 2022 (EUR Billion)
Table 16.31 GlaxoSmithKline: Annual Revenues, 2017 -H1 2022 (GBP Billion)
Table 16.32 Lonza: Annual Revenues, 2017-H1 2022 (CHF Billion)
Table 16.33 Pierre Fabre: Annual Revenues, 2018- 2021 (EUR Billion)
Table 16.34 Wacker Chemie ( a parent company of Wacker Biotech): Annual Revenues, 2017-H1 2022 (EUR Billion)
Table 16.35 Aenova: Annual Revenues, 2018-2021 (EUR Million)
Table 16.36 Fresenius Kabi: Annual Revenues, 2017-9M 2022 (EUR Billion)
Table 16.37 Recipharm: Annual Revenues, 2017- 2020 (SEK Billion)
Table 16.38 Recipharm: Revenues by Business Divisions, 2020 (SEK Billion)
Table 16.39 Asymchem: Annual Revenues, 2017-2020 (USD Billion)
Table 16.40 Samsung Biologics: Annual Revenues, 2017-H1 2022 (KRW Billion)
Table 16.41 Syngene: Annual Revenues, FY 2017-FY 2022 (INR Million)
Table 16.42 Takara Bio: Annual Revenues, FY 2017-FY 2022 (JPY Billion)
Table 16.43 WuXi Biologics: Annual Revenues, 2017-H1 2022 (RMB Million)
Table 16.44 Siegfried: Annual Revenues, 2017-H1 2022 (CHF Million)
Table 16.45 Wockhardt: Annual Revenues, FY 2017- FY Q1 2023 (INR Billion)
Table 16.46 Partnerships and Collaborations: Cumulative Year wise Trend, 2013-2022
Table 16.47 Partnerships and Collaborations: Distribution by Type of Partnership
Table 16.48 Partnerships and Collaborations: Distribution by Scale of Operation
Table 16.49 Partnerships and Collaborations: Distribution by Type of Molecule(s) Involved
Table 16.50 Partnerships and Collaborations: Distribution by Type of Service(s) Offered
Table 16.51 Partnerships and Collaborations: Distribution by Type of Process(es) Involved
Table 16.52 Partnerships and Collaborations: Distribution by Type of Drug Product(s) Involved
Table 16.53 Most Active Players: Distribution by Number of Partnerships
Table 16.54 Partnerships and Collaborations: Distribution by Geography
Table 16.55 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Table 16.56 Global Aseptic Fill Finish Manufacturing Market, 2023-2035 (USD Billion)
Table 16.57 Aseptic Fill Finish Manufacturing Market, Conservative, Base and Optimistic Scenarios: Distribution by Type of Molecule, 2023-2035 (USD Billion)
Table 16.58 Aseptic Fill Finish Manufacturing Market, Conservative, Base and Optimistic Scenarios: Distribution by Type of Packaging Container Offered, 2023-2035 (USD Billion)
Table 16.59 Aseptic Fill Finish Manufacturing Market, Conservative, Base and Optimistic Scenarios: Distribution by Type of Drug Product, 2023-2035 (USD Billion)
Table 16.60 Aseptic Fill Finish Manufacturing Market, Conservative, Base and Optimistic Scenarios: Distribution by Target Therapeutic Area, 2023-2035 (USD Billion)
Table 16.61 Aseptic Fill Finish Manufacturing Market, Conservative, Base and Optimistic Scenarios: Distribution by Scale of Operation, 2023-2035 (USD Billion)
Table 16.62 Aseptic Fill Finish Manufacturing Market, Conservative, Base and Optimistic Scenarios: Distribution by Company Size, 2023-2035 (USD Billion)
Table 16.63 Aseptic Fill Finish Manufacturing Market, Conservative, Base and Optimistic Scenarios: Distribution by Geography, 2023-2035 (USD Billion)
Table 16.64 Aseptic Fill Finish Manufacturing Market for Biologics, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 16.65 Aseptic Fill Finish Manufacturing Market for Biologics, Conservative, Base and Optimistic Scenarios: Distribution by Type of Packaging Container Offered, 2023-2035 (USD Billion)
Table 16.66 Aseptic Fill Finish Manufacturing Market for Biologics, Conservative, Base and Optimistic Scenarios: Distribution by Type of Drug Product, 2023-2035 (USD Billion)
Table 16.67 Aseptic Fill Finish Manufacturing Market for Biologics, Conservative, Base and Optimistic Scenarios: Distribution by Target Therapeutic Area, 2023-2035 (USD Billion)
Table 16.68 Aseptic Fill Finish Manufacturing Market for Biologics, Conservative, Base and Optimistic Scenarios: Distribution by Scale of Operation, 2023-2035 (USD Billion)
Table 16.69 Aseptic Fill Finish Manufacturing Market for Biologics, Conservative, Base and Optimistic Scenarios: Distribution by Company Size, 2023-2035 (USD Billion)
Table 16.70 Aseptic Fill Finish Manufacturing Market for Biologics, Conservative, Base and Optimistic Scenarios: Distribution by Geography, 2023-2035 (USD Billion)
Table 16.71 Aseptic Fill Finish Manufacturing Market for Small Molecules, Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Billion)
Table 16.72 Aseptic Fill Finish Manufacturing Market for Small Molecules, Conservative, Base and Optimistic Scenarios: Distribution by Type of Packaging Container Offered, 2023-2035 (USD Billion)
Table 16.73 Aseptic Fill Finish Manufacturing Market for Small Molecules, Conservative, Base and Optimistic Scenarios: Distribution by Scale of Operation, 2023-2035 (USD Billion)
Table 16.74 Aseptic Fill Finish Manufacturing Market for Small Molecules, Conservative, Base and Optimistic Scenarios: Distribution by Company Size, 2023-2035 (USD Billion)
Table 16.75 Aseptic Fill Finish Manufacturing Market for Small Molecules, Conservative, Base and Optimistic Scenarios: Distribution by Geography, 2023-2035 (USD Billion)